Therefore chemotherapy is still recommended as the 1st-line treatment for stage IV NSCLC patients without EGFR mutation, ALK fusion gene arrangement or unknown for these gene mutation statuses in the NCCN guideline. This evidence concerns the gene EGFR and non-small cell lung carcinoma.